Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc.
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: New York, N.Y., September 28, 2026. Rosen Law Firm, a global investor rights ...
Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY ...
Hosted on MSN
Unicycive Therapeutics announces second quarter 2026 financial results and provides business update
Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor FDA has assigned a facility ...
NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 ...
We’re focused on securing approval of oxylanthanum carbonate and remain confident in the efficacy and safety of OLC and in its potential to improve care for patients with hyperphosphatemia on dialysis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results